Trial Search Results

Midostaurin in Treating Older Patients With Mutated Acute Myeloid Leukemia Post-Transplant

This phase 2 trial studies the side effects and how well midostaurin works in treating older patients with acute myeloid leukemia with change in genetic material post-hematopoietic cell transplantation. Midostaruin may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving midostaruin post-transplant may improve patient outcomes.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Stanford University

Stanford Investigator(s):

Intervention(s):

  • Drug: Midostaurin

Phase:

Phase 2

Eligibility


INCLUSION CRITERIA

   - Elderly patients with FLT3-mutated acute myeloid leukemia (AML)

   - Prior enrollment in Stanford study IRB-25737

   - In continued complete remission

   - ≥ 30 days but ≤ 90 days post allogeneic hematopoietic cell transplant (HCT); treatment
   on this study protocol must begin before day 90 post-HCT

   - Absolute neutrophil count (ANC) ≥ 1000 cells/uL

   - Hemoglobin ≥ 8.0 g/dL and not requiring regular transfusions

   - Platelets ≥ 50,000 cells/uL and not requiring regular transfusions

   - Aspartate aminotransferase (AST) ≤ 2.5 times upper limit of normal (ULN)

   - Alanine aminotransferase (ALT) ≤ 2.5 X ULN

   - Serum bilirubin ≤ 2.5 times ULN

   - Ability to give written informed consent, including via legally authorized
   representative

   - Corrected QT (QTc) ≤ 450 msec

   - Ejection fraction (EF) ≥ 45% by 2-dimensional transthoracic echocardiography (TTE) or
   multiple-gated acquisition (MUGA)

   - Sexually active males, including vasectomized males, must agree via informed consent
   to use a condom during vaginal, anal, or oral intercourse, while taking midostaurin
   and for 5 months after stopping midostaurin

   - Females must have or be:

      - Negative pregnancy test, within 21 days of the first dose of midostaurin OR

      - Not of childbearing potential as follows:

         - Has undergone a hysterectomy or bilateral oophorectomy;

         - Has not had menses at any time in the preceding 24 consecutive months

EXCLUSION CRITERIA

   - Uncontrolled acute graft-vs-host disease (GVHD) grade 3 to 4

   - Uncontrolled active infection

   - Evidence of active AML (eg, circulating peripheral blasts on complete blood count)

   - Known confirmed diagnosis of human immunodeficiency virus (HIV) infection

   - Known confirmed diagnosis of active viral hepatitis

   - QTc > 450 msec

   - Congenital long QT syndrome

   - History of presence of sustained ventricular tachycardia, history of ventricular
   fibrillation or torsades de pointes

   - Bradycardia defined as heart rate (HR) < 50 beats per minute (bpm)

   - Bifascicular block (right bundle branch block plus left anterior hemiblock)

   - Congestive heart failure (CHF) New York Heart Association (NYHA) class 3 or 4

   - Cardiac ejection fraction (EF) < 45% within 28 days prior to starting cycle 1

   - Other known malignancy (except carcinoma in situ)

   - Other concurrent severe and/or uncontrolled medical condition which could compromise
   participation in the study, eg:

      - Uncontrolled diabetes

      - Chronic active pancreatitis

      - Myocardial infarction within 6 months

      - Poorly-controlled hypertension

      - Chronic kidney disease

   - Received any investigational agent within 30 days prior to day 1

   - Antineoplastic chemotherapy or radiotherapy within 28 days prior to cycle 1

   - No plans for concurrent chemotherapy while on study (exception: antineoplastic drugs
   used as part of GVHD prophylaxis or treatment)

   - Any surgical procedure, excluding central venous catheter placement, bone marrow
   biopsy or other minor procedures (eg, skin biopsy) within 14 days of day 1

   - Unwillingness or inability to comply with the protocol

   - Known malignant disease of the central nervous system

   - History of allergic reactions attributed to compounds of similar chemical or biologic
   composition to midostaurin

   - Concomitant use of strong inhibitors of cytochrome P450 family 3 subfamily A member 4
   (CYP3A4)

   - Pregnant or lactating

   - Women of child-bearing potential

Ages Eligible for Study

60 Years - N/A

Genders Eligible for Study

All

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Jack Taw
650-723-2781
Not Recruiting